Biogen shares have a lot more potential upside thanks to positive new data around the company's early Alzheimer's drug, Goldman Sachs said Wednesday. ...
Continue reading the above news article, by clicking here.
Administration and Moderation NOTE: A Reminder, the above news is provided for free, through a RSS Feed. The above quote does NOT include the full story. In order to continue to read more past what is quoted, please click through to the article, by clicking on the link provided above through the "continue reading" text.
Please be sensible and follow our terms of service and rules, when replying and debating the news article.